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CHEK2 (previously known as “CHK2”) is a cell-cycle–checkpoint kinase that phosphorylates p53 and BRCA1 in
response to DNA damage. A protein-truncating mutation, 1100delC in exon 10, which abolishes the kinase function
of CHEK2, has been found in families with Li-Fraumeni syndrome (LFS) and in those with a cancer phenotype
that is suggestive of LFS, including breast cancer. In the present study, we found that the frequency of 1100delC
was 2.0% among an unselected population-based cohort of 1,035 patients with breast cancer. This was slightly,
but not significantly ( ), higher than the 1.4% frequency found among 1,885 population control subjects.Pp .182
However, a significantly elevated frequency was found among those 358 patients with a positive family history
(11/358 [3.1%]; odds ratio [OR] 2.27; 95% confidence interval [CI] 1.11–4.63; , compared with pop-Pp .021
ulation controls). Furthermore, patients with bilateral breast cancer were sixfold more likely to be 1100delC carriers
than were patients with unilateral cancer (95% CI 1.87–20.32; ). Analysis of the 1100delC variant in anPp .007
independent set of 507 patients with familial breast cancer with no BRCA1 and BRCA2 mutations confirmed a
significantly elevated frequency of 1100delC (28/507 [5.5%]; OR 4.2; 95% CI 2.4–7.2; ), comparedPp .0002
with controls, with a high frequency also seen in patients with only a single affected first-degree relative (18/291
[6.2%]). Finally, tissue microarray analysis indicated that breast tumors from patients with 1100delC mutations
show reduced CHEK2 immunostaining. The results suggest that CHEK2 acts as a low-penetrance tumor-suppressor
gene in breast cancer and that it makes a significant contribution to familial clustering of breast cancer—including
families with only two affected relatives, which are more common than families that include larger numbers of
affected women.
Cell-cycle–checkpoint kinase 2 (CHEK2 [MIM 604373])
(previously known as “CHK2”), a human homologue of
budding yeast (Schizosaccharomyces pombe) Cds1 and
fission yeast Rad53, is one of the key mediators of cellular
responses to DNA damage (Zhou and Elledge 2000; Bar-
tek et al. 2001). CHEK2 is part of the p53 pathway and
modulates the function of p53 by phosphorylating it in
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response to DNA damage, leading to cell-cycle arrest at
G1 (Chehab et al. 2000; Shieh et al. 2000). CHEK2 also
regulates the function of the BRCA1 protein after DNA
damage (Lee et al. 2000). Its upstream regulator in the
p53 pathway is the checkpoint protein kinase ATM
(Kastan and Lim 2000), which activates CHEK2 by phos-
phorylation in response to double-strand DNA breaks
(Matsuoka et al. 1998, 2000). CHEK2 is thus a com-
ponent of major functional networks that control cell cy-
cle and DNA repair, as are the most important suscep-
tibility genes in hereditary cancer syndromes. In addition,
CHEK2 has been found to undergo somatic mutations
in a number of cancer types, including lung, ovarian,
and lymphoid tumors and sarcomas, as well as in my-
elodysplastic syndrome (Bell et al. 1999; Haruki et al.
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Table 1
Frequency of the CHEK2 1100delC Mutation in the Cohorts of Unselected Patients and Patients with Familial





Mutation (%) ORa 95% CI P
Population controls 1,885 26 (1.4)
Unselected patients with breast cancer: 1,035 21 (2.0) 1.48 .83–2.65 .182
No family history 677 10 (1.5)
1 Affected first- or second-degree relative 358 11 (3.1) 2.27 1.11–.63 .021
Breast cancer only 318 11 (3.5) 2.56 1.25–5.23 .008
Breast and ovarian cancer 40 0
Patients with familial breast cancer: 507 28 (5.5) 4.18 2.4–7.2 .0002
By type(s) of cancer:
Breast cancer only 448 23 (5.1) 3.87 2.19–6.85 !.00005
Breast and ovarian cancer 59 4 (6.8) 5.20 1.75–15.41 .012
By no. of affected relatives:
Index with 1 affected first-degree relative 291 18 (6.2) 4.70 2.55–8.71 !.00005
3 Affected family membersb: 216 10 (4.6) 3.50 1.65–7.3 .002
Index with affected first-degree relatives 164 7 (4.3) 3.19 1.36–7.46 .013
Index with affected second-degree relatives only 52 3 (5.8) 4.38 1.28–14.95 .041
a Compared with population control subjects.
b First- or second-degree relatives with breast or ovarian cancer (including the index patient).
2000; Hofmann et al. 2001; Tavor et al. 2001; Miller
et al. 2002). Recently, rare germline missense variants
of CHEK2 were reported in families with multicancer
Li-Fraumeni syndrome (LFS [MIM 151623]) (Bell et al.
1999; Lee et al. 2001; Vahteristo et al. 2001b). Inter-
estingly, however, the same recurrent protein-truncating
mutation—1100delC in exon 10, which abolishes the
kinase function of CHEK2 (Wu et al. 2001)—has been
reported both among families with LFS in the United
States and among Finnish families with a cancer pheno-
type that is suggestive of LFS, including breast cancer
(Bell et al. 1999; Vahteristo et al. 2001b). This finding
prompted us to determine the significance of this CHEK2
genetic variant for breast cancer susceptibility in a large
study involving germline-mutation screening of 13,000
individuals. In addition, we compared germline CHEK2
mutation data with analysis of CHEK2 protein expres-
sion in breast tumors by use of tissue microarrays.
We first determined the frequency of the 1100delC
variant in a population-based cohort of 1,035 unse-
lected patients with breast cancer from the Helsinki
( ) and Tampere ( ) University Hospi-Np 627 Np 408
tals and in 1,885 healthy population controls from the
Finnish Red Cross Blood Transfusion Service. The breast
cancer cohort includes 82% (87% in Helsinki and 75%
in Tampere) of all newly diagnosed patients with breast
cancer in these hospital districts during 1997–1999. This
population-based cohort is described in more detail else-
where (Syrjakoski et al. 2000), and 4 breast cancer type
1 (BRCA1 [MIM 113705]) and 15 breast cancer type
2, early onset (BRCA2 [MIM 600185]) mutations were
discovered in these patients (total frequency 1.8%). For
all the cohorts of patients included in the present study,
blood samples were collected after obtaining written in-
formed consent and appropriate permissions from the
ethics committees of the Departments of Obstetrics and
Gynecology and of Oncology at Helsinki University Cen-
tral Hospital and Tampere University Hospital, as well as
from the Ministry of Social Affairs and Health in Finland.
Because the DNA sequence containing exon 10 of CHEK2
is present in multiple homologous copies in the genome,
specific PCR primers for the CHEK2 exon 10 on chro-
mosome 22 were designed to avoid all other homologous
sequences, as described elsewhere (forward primer 5′-TTA
ATT TAA GCA AAA TTA AAT GTC-3′; reverse primer
5′-GGC ATG GTG GTG TGC ATC-3′) (Vahteristo et al.
2001b). We applied minisequencing (primer extension)
(Syvanen et al. 1993) for the mutation detection, and all
positive minisequencing results were confirmed by ream-
plification from the original genomic DNA sample and
by direct sequencing. In the statistical analyses, differ-
ences in continuous variables were evaluated by use of
the Mann-Whitney test (SPSS, version 8.0), and differ-
ences in dichotomous variables were evaluated by x2 test
or by Fisher’s exact test. All P values are two sided.
The frequency of the 1100delC variant among pop-
ulation controls was 1.4% (26/1,885) (table 1). Among
the unselected patients with breast cancer, a slightly
higher frequency (2.0% [21/1,035]) was seen (odds ratio
[OR] 1.48; 95% CI 0.83–2.65; ). Of those 358Pp .182
patients who reported at least one first- or second-degree
relative affected with breast or ovarian cancer, 11 (3.1%)
carried the 1100delC variant (OR 2.27; 95% CI 1.11–
4.63; , compared with population control sub-Pp .021
jects). The frequency of 1100delC among 677 patients
with no family history of breast cancer (1.5%) was sim-
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Figure 1 Pedigrees of two families with a CHEK2 1100delC
germline variant. In family 178 (top), four patients with breast cancer
share the mutation, but four unaffected women are also carriers. In
family 277 (bottom), the mutation is found only in one patient with
breast cancer and her unaffected sister. Prca p prostate cancer; Brca
p breast cancer;  p positive for mutation;  p negative for mu-
tation. Numbers followed by “y” represent age at diagnosis, except
for two women in family 277, whose age is preceded by “d,” repre-
senting age at death.
ilar to that seen in control individuals. In the same cohort
of 1,035 patients with breast cancer, 19 (1.8%) carried
BRCA1 or BRCA2 mutations (4.2% of the 358 patients
with a positive family history). CHEK2 and BRCA mu-
tations were seen in different kinds of patients with fa-
milial breast cancer. Most BRCA1 and BRCA2 muta-
tions (11/19 [58%]) were found in patients with a strong
family history (three or more first- or second-degree rel-
atives with breast or ovarian cancer in the family [in-
cluding the index patient]), whereas only 3/21 (14%) of
CHEK2 variants were found among this group. All
CHEK2 variants were found in patients who tested neg-
ative for BRCA1 and BRCA2 mutations. Taken together,
the results suggest that CHEK2 1100delC variant is as-
sociated with positive family history of breast cancer,
independently of BRCA1 and BRCA2 mutations.
We further examined the significance of CHEK2 in
non-BRCA1/2 familial breast cancer in an independent,
large cohort of 507 patients, consisting exclusively of
those with positive family history. These included 216
BRCA1/2-mutation–negative patients with breast cancer
(index cases from the families) who had a strong family
history (three or more first- or second-degree relatives
with breast or ovarian cancer [including the index pa-
tient]), as verified by links to the Finnish Cancer Registry
and to hospital records. In addition, we examined 291
unrelated, BRCA1/2 mutation-negative patients with
breast cancer who reported only a single affected first-
degree relative. The patients with familial breast cancer
were identified at the Helsinki University Central Hos-
pital, as described elsewhere (Vehmanen et al. 1997;
Eerola et al. 2000; Vahteristo et al. 2001a,), and BRCA1/
2 mutations were excluded, as described elsewhere (Veh-
manen et al. 1997, Vahteristo et al. 2001a).
The 507 patients with familial breast cancer included
28 (5.5%) patients who carried the 1100delC variant, a
significantly higher frequency than is seen in population
control individuals (OR 4.18, 95% CI 2.4–7.2; Pp
). The frequency of 1100delC was significantly el-.0002
evated, in comparison with population control subjects,
both among patients with only one affected first-degree
relative (18/291 [6.2%]; OR 4.7; 95% CI 2.55–8.71;
), as well as in patients with a strong familyP ! .00005
history (10/216 [4.6%]; OR 3.5; 95% CI 1.65–7.3;
). Frequencies among index patients with aPp .002
strong family history, with or without an affected first-
degree relative, are shown in table 1. All carriers iden-
tified in the different study cohorts were heterozygous
for the mutation. Segregation of the CHEK2 variant was
tested in the five CHEK2-positive families that had a
sufficient number of affected family members available
for sampling. Pedigrees of two families are shown in
figure 1. Although the mutation was shared among sev-
eral patients in the five families, segregation of the mu-
tation with the disease was incomplete, in that both un-
affected mutation carriers and mutation-negative
patients with breast cancer were observed. The obser-
vation of unaffected carriers, as well as the strong as-
sociation of the 1100delC variant with patients who had
only a moderate family history, suggests that the CHEK2
1100delC variant has low penetrance. Furthermore, al-
though the CHEK2 1100delC mutation is more frequent
in patients with familial breast cancer, it alone may not
explain the clustering of the disease in the pedigrees, in
which, presumably, other, unknown predisposition al-
leles may also segregate. According to recent epidemi-
ological evidence from studies of patients with breast
cancer and their families, non-BRCA1/2 familial aggre-
gation of breast cancer may be caused by multiplicative
effects of low-penetrance genes (Antoniou et al. 2001,
2002). Although several common polymorphisms have
been reported to have a slightly higher frequency among
patients with breast cancer than among control individ-
uals (Dunning et al. 1999), none of these have been
shown to be associated with family history of the disease.
The CHEK2 1100delC mutation may therefore be the
first example of a low-penetrance genetic alteration that
contributes significantly to familial clustering of breast
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cancer at the population level and also in families with
small numbers of affected relatives.
Some phenotypic features of patients with breast can-
cer who carry the CHEK2 mutation deserve attention.
First, we observed a strong association of the 1100delC
variant with bilateral breast cancer. Among the 627
unselected patients with breast cancer for whom in-
formation on laterality was available, there were 33
patients with bilateral breast cancer, of whom 4 (12.1%)
carried the mutation (OR 6.17; 95% CI 1.87–20.32;
), compared with 12 (2.0%) of the 594 patientsPp .007
with unilateral disease. Two of these CHEK2-positive
patients had a family history of breast cancer. We have
elsewhere reported an elevated risk of a second, contra-
lateral breast cancer in BRCA1/2-mutation–negative
families with breast cancer (Eerola et al. 2001). The pos-
sibility that this could be related to the CHEK2
1100delC variant warrants further investigation. Sec-
ond, there was no association of 1100delC mutation
with ovarian cancer. In the familial cohort, the frequency
of 1100delC was similar in families with and without
members who had ovarian cancer ( ; table 1),Pp .54
and all 11 mutations among patients with familial dis-
ease in the unselected cohort were found in patients
whose family history included only breast cancer (table
1). Third, the mean age at onset of the CHEK2 carriers
in all of the patient cohorts was 52.7 years, an age only
marginally different from the mean age of patients with
no mutations (54.8 years; ). A similar trendPp .062
was observed in the cohort of unselected patients (54.7
vs. 57.4 years; ). These results contrast withPp .292
the ovarian cancer association and the earlier age at
disease onset that are observed among carriers of
BRCA1 and BRCA2 mutations, compared with those of
noncarriers. In our earlier study of the same cohort (Syr-
jakoski et al. 2000), this difference was 8 years (49.7
years vs. 57.5 years; ). Therefore, these re-Pp .026
sults further support the role of CHEK2 1100delC
mutation as a distinct allele that predisposes carriers
to disease and whose effects are not seen as a shift in
the age at diagnosis.
We also explored whether the germline 1100delC mu-
tation is associated with the expression of the CHEK2
protein in tumor tissues. A tissue microarray containing
124 tumors from BRCA1/2-mutation–negative families
was constructed and was stained with a mouse mono-
clonal antibody, DCS-270, against the human CHEK2
protein. The antibody and protocols for sensitive im-
munoperoxidase staining of human tissues have been
described elsewhere (Bartkova et al. 2001; Lukas et al.
2001). The staining results were evaluated without prior
knowledge of the mutation status of CHEK2. Specificity
and reproducibility controls included lack of staining
with DCS-270 preabsorbed with recombinant CHEK2
protein, consistency of staining patterns between two
different samples from each of the tumors present on
the array, parallel staining of normal breast tissues under
identical conditions, and parallel staining of the array
with an unrelated monoclonal antibody. Given the re-
producible detection of CHEK2 in 70%–90% of luminal
epithelial cells in normal breast tissues present on the
microarray (as well as cells examined on parallel sec-
tions), we considered that the staining of tumors was
aberrantly reduced when either a lower CHEK2-staining
intensity was seen or when the percentage of CHEK2-
positive cells was !50%. Overall, reduced CHEK2 pro-
tein expression (fig. 2) was observed in 21/124 (16.9%)
breast tumors. The array included four breast tumors
from four CHEK2 1100delC germline carriers from dif-
ferent families (including pedigrees from families 178 and
277 shown in fig. 1). All four of these patients showed
reduced CHEK2 expression (fig. 2). The 1100delC germ-
line variant was therefore seen in 4/21 (19%) patients
with reduced expression of the CHEK2 protein; in con-
trast, none of the 103 patients with normal CHEK2-
staining pattern showed mutations ( ). The factP ! .0005
that all tumors from patients with germline CHEK2
1100delC showed reduced immunostaining for CHEK2
supports the role of the germline variant in influencing
CHEK2 protein levels, as well as its possible functional
inactivation in tumorigenesis. Three of these four tumors
were among the most grossly defective in CHEK2 stain-
ing, suggesting that the second allele was probably lost.
Because the DCS-270 epitope lies within the N-terminus
of CHEK2 (Lukas et al. 2001) (a part of the protein that
is preserved in CHEK2 1100delC), this genetic variant
may affect the expression and/or stability of CHEK2 in
addition to the kinase activity.
In conclusion, our results indicate that the1100delC
genetic variant of the CHEK2 tumor-suppressor gene,
previously demonstrated to abolish the kinase activity
of the CHEK2 protein (Wu et al. 2001), is significantly
associated with positive family history of breast cancer
in two distinct patient cohorts. A high frequency of this
CHEK2 mutation was seen also in patients belonging to
families with small numbers of affected relatives. The
clustering of this variant in families with small numbers
of affected relatives, the incomplete segregation in fam-
ilies with a larger number of affected relatives, and the
absence of an association with ovarian cancer and early
age at breast cancer onset all support the hypothesis that
1100delC is acting as a low-penetrance predisposition
allele, with distinctly different phenotypic consequences,
as seen in carriers of BRCA1/2 mutations. The strong
association of the CHEK2 1100delC with families that
include two affected patients is important, because these
are the most common types of breast cancer families. In
our recent large epidemiological survey, 16.7% of pa-
tients with breast cancer reported only a single affected
first-degree relative, whereas 6.9% had two or more af-
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Figure 2 Immunohistochemical detection of CHEK2 in human breast tissues and tumors on a tissue microarray. Examples include breast
carcinomas with normal (panels A and H) or aberrantly reduced (panels B, C, D, E, F, G and I) CHEK2 levels, compared with normal breast
tissue control (panel J). The samples shown in panels B, C, and D are from three different tumors with 1100delC, and corresponding detailed
staining patterns are documented in panels E, F, and G, respectively. Panel I shows reduced CHEK2 immunostaining in a breast carcinoma
wild type for exon 10. The incubation with the DCS-270 antibody and biotin-streptavidin-peroxidase detection was not followed by nuclear
counterstaining (Bartkova et al. 2001; Lukas et al. 2001), to facilitate evaluation of the CHEK2 staining intensity in the nuclei of tumor cells,
normal epithelial cells, and stromal cells. Note the reduced staining for CHEK2 in panels B, C, D, E, F, G, and I, compared with normal levels
seen in panels A, H, and J. Magnification 30#, in panels A–D, and 120#, in panels E–J.
fected relatives (Eerola et al. 2000). A genetic alteration
such as CHEK2 1100delC is therefore likely to have a
significant contribution to familial breast cancer at the
population level, although it alone may not be suitable
in guiding genetic counseling of individual patients or
families. Finally, the 1100delC was sixfold more fre-
quent in patients with bilateral breast cancer than in
patients with unilateral disease. If confirmed by addi-
tional studies, this observation could, in the future, have
a direct impact on patient management and follow-up.
Note added in manuscript.—While this manuscript
was under review, another study was published that
reported a similar strong association between the CHEK2
1100delC allele and familial breast cancer (CHEK2
Breast Cancer Consortium). Female carriers of the
1100delC allele were estimated to have a twofold in-
crease in breast cancer risk, and the allele was found to
have a 1.1% population prevalence among healthy in-
dividuals in the United Kingdom, The Netherlands, and
North America. The carriers were found to share a com-
mon allele at a CHEK2 intragenic microsatellite marker
D22S275, which may indicate that this predisposition
allele with a wide distribution in different populations
may have a very ancient common origin. Taken together
with our results, the studies confirm CHEK2 1100delC
as a low-penetrance breast cancer–predisposition allele.
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